公司概覽
業務類別 Biotechnology
業務概覽 Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer andmetastatic castration-resistant prostate cancer, are ongoing.
公司地址 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
電話號碼 +1 763 392-0767
傳真號碼 --
公司網頁 https://www.celcuity.com
員工數量 155
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Brian F. Sullivan Chairman of the Board and Chief Executive Officer 美元 577.10K 02/04/2026
Ms. Vicky Hahne Chief Financial Officer and Principal Accounting Officer 美元 419.60K 02/04/2026
Dr. Lance G. Laing Director, Chief Science Officer, Vice President and Secretary 美元 472.56K 02/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Brian F. Sullivan Chairman of the Board and Chief Executive Officer 02/04/2026
Mr. David W. Gryska, M.B.A. Independent Director 02/10/2026
Mr. Richard J. Nigon Independent Director 02/04/2026
Mr. David F. Dalvey Independent Director 02/04/2026
Dr. Lance G. Laing Director, Chief Science Officer, Vice President and Secretary 02/04/2026
Dr. Leo T. Furcht, M.D. Independent Director 02/04/2026
Dr. Richard E. Buller, M.D.,PhD Independent Director 02/04/2026
Mr. Charles R. Romp Independent Director 02/04/2026
Dr. Polly A. Murphy, D.V.M.,PhD Independent Director 02/04/2026
 
所屬ETF (更新日期: 14/11/2026 03:27)
代號 名稱 佔比% ▼ 持有日期
GABGabelli Equity Trust0.001%30/06/2026
PWSPacer WealthShield ETF0.001%30/10/2026
FSEGFidelity Enhanced Small Cap Growth ETF0.0003%30/10/2026
RESMColumbia Research Enhanced Small Cap ETF0.0002%31/10/2026
SSMGVirtus Silvant Small/Mid Growth ETF0.0002%30/10/2026
FFFFounders 100 ETF0.0001%30/10/2026
HDGProShares Hedge Replication0.0001%30/10/2026
RBProshares Russell 2000 Dynamic BufferETF0.00003%30/10/2026
AAUBAlpha Architect US Equity 4 ETF<0.000001%28/08/2026
AVIEAvantis Inflation Focused Equity ETF<0.000001%10/06/2026
DFSUDimensional US Sustainability Core 1 ETF<0.000001%12/08/2025
DWASInvesco Dorsey Wright SmallCap Momt ETF<0.000001%01/07/2026
ESSCEventide Small Cap ETF<0.000001%19/10/2026
FRTYAlger Mid Cap 40 ETF<0.000001%03/06/2026
FSCCFederated Hermes MDT Small Cap Core ETF<0.000001%21/08/2026
FSEVFidelity Enhanced Small Cap Value ETF<0.000001%15/06/2026
FSMLFranklin Small Cap Enhanced ETF<0.000001%21/05/2026
FTLSFirst Trust Long/Short Equity ETF<0.000001%04/06/2026
HIAIAi Funds High Conv US Eq AI-Mgd ETF<0.000001%21/09/2026
ISCGiShares Morningstar Small-Cap Growth ETF<0.000001%18/06/2026
  1    2   3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.